Publicaties
Gekozen filters:
Gekozen filters:
Function of PP2A methylesterase-1 PME-1 in the stress response: implications for glioblastoma treatment KU Leuven
Glioblastoma (GBM) is the most common primary brain tumor in adults. Current standard therapy is surgery followed by radiotherapy, with concurrent and adjuvant temozolomide (TMZ) chemotherapy. GBM is characterized by almost uniformly fatal outcome, highlighting the unmet clinical need for more efficient, biomarker-guided treatments. Protein phosphatase methylesterase-1 (PME-1), a regulator of the tumor suppressive phosphatase PP2A, promotes PP2A ...
Preclinical Targeted α- and β−-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies Vrije Universiteit Brussel
HER2-targeted therapies have drastically improved the outcome for breast cancer patients. However, when metastasis to the brain is involved, current strategies fail to hold up to the same promise. Camelid single-domain antibody-fragments (sdAbs) have been demonstrated to possess favorable properties for detecting and treating cancerous lesions in vivo using different radiolabeling methods. Here we evaluate the anti-HER2 sdAb 2Rs15d, coupled ...
Novel combination immunotherapy for pancreatic cancer: potent anti-tumor effects with CD40 agonist and interleukin-15 treatment Universiteit Antwerpen
Objectives With the poorest 5-year survival of all cancers, improving treatment for pancreatic cancer is one of the biggest challenges in cancer research. We sought to explore the potential of combining both priming and activation of the immune system. To achieve this, we combined a CD40 agonist with interleukin-15 and tested its potential in pancreatic cancer. Methods Response to this combination regimen was assessed in pancreatic ductal ...
Clinically relevant chemotherapeutics have the ability to induce immunogenic cell death in non-small cell lung cancer Universiteit Antwerpen
The concept of immunogenic cell death (ICD) has emerged as a cornerstone of therapy-induced anti-tumor immunity. To this end, the following chemotherapies were evaluated for their ability to induce ICD in non-small cell lung cancer (NSCLC) cell lines: docetaxel, carboplatin, cisplatin, oxaliplatin and mafosfamide. The ICD hallmarks ATP, ecto-calreticulin, HMGB1, phagocytosis and maturation status of dendritic cells (DCs) were assessed in vitro. ...
Immunotherapy with subcutaneous immunogenic autologous lysate against glioblastoma KU Leuven
Being diagnosed with glioblastoma (GBM) is related to a grim future, with patients showing a median overall survival of less than 15 months despite intensive radio- and chemotherapy. As a consequence, the scientific community is searching for adjuvant treatment modalities that might improve the outcome of this devastating disease. In this regard, immunotherapy has gained great interest. One immunotherapeutic strategy uses dendritic cells (DCs) ...
Building a bridge between chemotherapy and immunotherapy in malignant pleural mesothelioma Universiteit Antwerpen
In light of the promising results of immune checkpoint blockade (ICPB) in malignant pleural mesothelioma (MPM), we investigated the effect of different chemotherapeutic agents on the expression of immune checkpoints (ICPs) in order to rationally design a good treatment schedule for their combination with ICP blocking antibodies. Cisplatin, oxaliplatin and pemetrexed are interesting chemotherapeutic agents to combine with immunotherapy given ...